The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.

ABSTRACT: Human cytomegalovirus (HCMV) infection in utero can lead to congenital sensory neural hearing loss and mental retardation. Reactivation or primary infection can increase the morbidity and mortality in immune suppressed transplant recipients and AIDS patients. The current standard of care for HCMV disease is nucleoside analogs, which can be nephrotoxic. In addition resistance to current treatments is becoming increasingly common. In an effort to develop novel CMV treatments, we tested the effectiveness of the D-form of a novel heparan sulfate binding peptide, p5R_D, at reducing infection of ganciclovir (GCV) resistant HCMVs in vitro and MCMV in vivo. HCMV infection was reduced by greater than 90% when cells were pretreated with p5R_D. Because p5R_D acts by a me

SUBMITTER: Pitt EA 

PROVIDER: S-EPMC5099097 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature